Search terms
Burgdorf, Switzerland and Eindhoven, the Netherlands – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, and Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based HealthSuite digital platform. To this end, the companies have signed a memorandum of understanding and aim to sign the definitive agreements in the fourth quarter of 2018.
With the new SmartServices™, Ypsomed aims to extend its medical device business, by providing a new turnkey digital solution for medication adherence monitoring and smart device management to its pharmaceutical customers. Ypsomed’s SmartServices™ will be enabled by Philips’ HealthSuite digital platform, a cloud-based platform which was purpose-built for the complex challenges in healthcare, and provides tools and services focused on ease-of-integration, digital lifecycle management, and end-to-end security. The new digital services aim to address a wide range of device-oriented challenges and support self-medication services for patients across chronic disease states, such as diabetes, multiple sclerosis and rheumatoid arthritis.
Our partnership with Philips aims at embedding smart devices in a digital health ecosystem that simplifies access to therapy-relevant medication adherence data.
Ulrike Bauer
Senior Vice President Ypsomed Delivery Systems
“Our partnership with Philips aims at embedding smart devices in a digital health ecosystem that simplifies access to therapy-relevant medication adherence data,” said Ulrike Bauer, Senior Vice President Ypsomed Delivery Systems. “This will allow our pharmaceutical customers to focus on building therapy-specific digital solutions for patients, caregivers and physicians.”
“Integrating Ypsomed’s smart devices and data into the Philips HealthSuite ecosystem means pharma companies will be able to develop solutions that leverage HealthSuite’s secure, cloud-based services,” said Dale Wiggins, Business Leader HealthSuite digital platform at Philips. “It will shorten time-to-market, enable them to scale-up solutions in a secure HIPAA-compliant way, and allow them to integrate data from Ypsomed devices with other data sources to support many different value-added use cases.”
Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the mylife™ Diabetescare brand directly to patients or through pharmacies and clinics, and under YDS Ypsomed Delivery Systems umbrella brand for business-to-business sales to pharmaceutical companies.
Philips’ open HealthSuite digital platform addresses the growing need to break down the data silos that pervade today’s healthcare systems by enabling secure access to, and analysis of, clinical data from multiple medical devices. This new collaboration between Philips and Ypsomed aims to embed smart medical devices, such as Ypsomed’s YpsoMate® with SmartPilot™ combination, in a digital architecture that bridges therapy-specific care pathways rather than siloing them.
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2017 sales of EUR 17.8 billion and employs approximately 75,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Read MoreRead Less
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1,500 employees. Additional information is available under www.ypsomed.com.
Read MoreRead Less
Philips Group Press Office
Tel: +31 6 10 55 8116
Head of Investor Relations at Ypsomed Holding AG
Tel.: +41 34 424 35 55
